Published in Liver Cancer on March 01, 2014
New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol (2016) 0.79
Dose-response association between hepatitis B surface antigen levels and liver cancer risk in Chinese men and women. Int J Cancer (2016) 0.75
Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS One (2015) 0.75
Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice. Oncotarget (2017) 0.75
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA (1965) 6.21
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med (1999) 5.32
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (2013) 5.03
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int (2012) 4.52
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Observations on Australia antigen in Japanese. Vox Sang (1968) 2.57
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology (2010) 2.47
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol (2007) 1.85
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology (2007) 1.75
A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology (2012) 1.60
A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology (2010) 1.58
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res (2005) 1.51
Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology (2011) 1.49
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol (2006) 1.40
Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology (2010) 1.37
Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer (2012) 1.32
Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology (2012) 1.18
A new role for an old marker, HBsAg. J Hepatol (2010) 1.12
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat (2009) 1.06
Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. Eur J Gastroenterol Hepatol (2004) 1.03
Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis (2011) 0.98
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs (2009) 0.93
Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology (2011) 0.93
Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med (2006) 0.91
Management of patients with decompensated HBV cirrhosis. Semin Liver Dis (2003) 0.89
Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int (2005) 0.88
Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol (2012) 0.87
Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res (2011) 0.84
Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon. Liver Int (2011) 0.76
The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology (2015) 3.19
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer (2012) 1.36
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer (2014) 1.35
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology (2014) 1.22
Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer (2015) 1.12
Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol (2017) 0.91
Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. Cancer (2015) 0.85
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol (2016) 0.84
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol (2016) 0.79
Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer (2015) 0.79
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. Liver Int (2016) 0.78
International comparison of treatment outcomes based on staging systems. Hepatol Res (2007) 0.76
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol (2016) 0.76
A comparative evaluation of treatment methods for bile duct stones after hepaticojejunostomy between percutaneous transhepatic cholangioscopy and peroral, short double-balloon enteroscopy. Therap Adv Gastroenterol (2016) 0.75
Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease. Hepat Med (2015) 0.75
Inclusion of Journal of Medical Ultrasonics in MEDLINE. J Med Ultrason (2001) (2016) 0.75
Usefulness of a newly designed plastic stent for endoscopic re-intervention in patients with malignant hilar biliary obstruction. Endoscopy (2017) 0.75
Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology (2017) 0.75
Foreword to the WFUMB guidelines and recommendations on the clinical use of ultrasound elastography. Ultrasound Med Biol (2015) 0.75